Accelerating HCP Engagement in AML Through Real-Time Diagnosis Signals and Proprietary Business Rules
The challenge
The client needed to identify newly diagnosed AML cases and the HCPs managing them early enough to support timely treatment decisions. AML is an aggressive, fast-progressing cancer requiring immediate intervention. Pharma companies have traditionally relied on claims data to target HCPs, but claims may be submitted up to 90 days after diagnosis, delaying outreach beyond the treatment decision
Business-critical issues included:
- Delayed HCP targeting due to reliance on claims data
- Inaccurate coding and incomplete capture of clinical events
- Missed opportunities for therapy initiation in a fast-moving disease area
External factors:
- AML's sudden onset and rapid progression
- High variability in survival rates and treatment suitability
- Need for real-time, accurate patient identification
Our approach
Diaceutics deployed Signal, using proprietary Diagnostic Deductive Pathways (DDPs®), to identify newly diagnosed AML cases and the treating HCPs within 24 hours of lab results. Signal outputs were validated against claims data to assess both speed and accuracy.
Key activities included:
- Lab-based signals generated within 24 hours of results and delivered weekly
- Application of Diagnostic Deductive Pathways (DDPs®) to improve precision
- Tracking of identified cases for comparison with claims data
Collaboration model:
- Ongoing collaboration through weekly signal delivery and continuous validation
Results & impact
- 80+ newly diagnosed AML cases identified each week, with approximately 7% going on to receive treatment
- Identification of 6 eligible patients represented approximately $1.05 million in potential revenue, based on a therapy cost of approximately $175,000 per patient
- Newly diagnosed cases identified within 24 hours of lab results, compared with an average 38-day delay when relying on claims data
Why it matters
In a fast-moving disease such as AML, timing is critical. Signal helps you identify treating HCPs within 24 hours of a relevant lab result—rather than waiting weeks for claims data—so your teams can act while treatment decisions are still being made. That creates more opportunity to support timely therapy initiation, reach eligible patients and protect commercial value.
About Diaceutics
At Diaceutics, our vision is Precision for All: a future where every eligible patient is identified, diagnosed and receives the right therapy at the right time.
For more than 20 years, we have helped biopharma companies overcome the diagnostic and commercialization barriers that stand between scientific innovation and patient impact. Today, we combine diagnostic intelligence, expert insight and targeted engagement to unlock the full potential of diagnostic-driven therapies—and more life for the patients they are designed to serve.
Navigate complexity, accelerate adoption, and drive sustained growth.
Connect with us today to unlock your therapy's full potential.
